REGULATORY

MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period

September 15, 2017
The Ministry of Health, Labor and Welfare (MHLW) plans to launch discussions on the scope of elderly people who would be subject to vaccination with Pneumovax NP (pneumococcus vaccine) under Japan’s publicly funded immunization program following the current transition period.…

To read the full story

Related Article

REGULATORY

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…